FDA announced today that it has expanded the previous EUA it granted for the saliva-based COVID-19 test out of Rutgers University — allowing people to collect samples at home and return the samples to the Rutgers Clinical Genomics Laboratory in a sealed package for testing.

The news comes just weeks after FDA authorized an at-home COVID-19 diagnostic test from Laboratory Corporation of America (NYSE:LH) that uses a sample collected from the patient’s nose.

The Rutgers Clinical Genomics Laboratory test is presently the only authorized COVID-19 diagnostic test that uses saliva samples.

“This provides an additional option for the easy, safe and convenient collection of samples required for testing without traveling to a doctor’s office, hospital or testing site,” FDA Commissioner Dr. Stephen M. Hahn said in a news release.

“The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency,” Hahn said.

People self-collect the saliva using the Spectrum Solutions SDNA-1000 saliva collection device, packaged into a self-collection kit.